Skip to main content
. Author manuscript; available in PMC: 2018 Aug 15.
Published in final edited form as: Immunity. 2017 Aug 15;47(2):284–297.e5. doi: 10.1016/j.immuni.2017.07.020

Figure 2. Myeloid-specific deletion of Tet2 inhibits melanoma growth.

Figure 2

(A-C) YUMM1.7 melanoma cells were injected into WT and Mye-Tet2-null mice. (A) Mean tumor volume in WT and Mye-Tet2 null mice. n=7. (B) Tumor weights four weeks after tumor cell injection. n=6. (C) Pictures of tumors for (B). (D, E) B16-OVA melanoma cells were injected into WT and Mye-Tet2 null mice. (D) Mean tumor volume in WT and Mye-Tet2-null mice. n=5. (E) Tumor weights at the endpoint for (D). For all panels, *: P< 0.05; **: P < 0.01; ns: not significant. Data are representative of three (A-C) or two (D-E) independent experiments.